Pipeline

The Vaxxinity development pipeline is derived from our innovative, proprietary, proven synthetic peptide platform, which has allowed us to develop the first multitope peptide-based vaccine for COVID-19, as well as a new class of medicines for neurological diseases like Alzheimer’s and Parkinson’s with novel targets, and common chronic diseases like migraine and hyptercholesterolemia based on well validated targets. We call vaccine candidates based on our platform “Vaxxines.”

Vaxxinity Clinical Development Pipeline
Vaxxine Program (Target)
Indications
Preclinical
IND
Phase I
Phase II
Phase III
Marketed
Infectious Disease
Vaxxine Program (Target)
Indications
Preclinical
IND
Phase I
Phase II
Phase III
Vaxxine Program (Target)
Indications
Covid-19
95%
Preclinical
IND
Phase I
Phase II
Phase III
Marketed
Vaxxine Program (Target)
Indications
Preclinical
IND
Phase I
Phase II
Phase III
Vaxxine Program (Target)
Indications
Covid-19
65%
Preclinical
IND
Phase I
Phase II
Phase III
Marketed
Chronic Disease
Vaxxine Program (Target)
Indications
Preclinical
IND
Phase I
Phase II
Phase III
Vaxxine Program (Target)
Indications
Alzheimer’s
65%
Preclinical
IND
Phase I
Phase II
Phase III
Marketed
Vaxxine Program (Target)
Indications
Preclinical
IND
Phase I
Phase II
Phase III
Vaxxine Program (Target)
Indications
Parkinson’s, DLB, MSA
48%
Preclinical
IND
Phase I
Phase II
Phase III
Marketed
Vaxxine Program (Target)
Indications
Preclinical
IND
Phase I
Phase II
Phase III
Vaxxine Program (Target)
Indications
Chronic migraine
25%
Preclinical
IND
Phase I
Phase II
Phase III
Marketed
Vaxxine Program (Target)
Indications
Preclinical
IND
Phase I
Phase II
Phase III
Vaxxine Program (Target)
Indications
Alzheimer’s, PSP
10%
Preclinical
IND
Phase I
Phase II
Phase III
Marketed
Vaxxine Program (Target)
Indications
Preclinical
IND
Phase I
Phase II
Phase III
Vaxxine Program (Target)
Indications
C9orf ALS/FTD
10%
Preclinical
IND
Phase I
Phase II
Phase III
Marketed
Vaxxine Program (Target)
Indications
Preclinical
IND
Phase I
Phase II
Phase III
Vaxxine Program (Target)
Indications
Hypercholesterolemia
10%
Preclinical
IND
Phase I
Phase II
Phase III
Marketed
Validated Target
Vaxxine Program (Target)
Indications
Preclinical
IND
Phase I
Phase II
Phase III
Vaxxine Program (Target)
Indications
Alzheimer’s
65%
Preclinical
IND
Phase I
Phase II
Phase III
Marketed
Vaxxine Program (Target)
Indications
Preclinical
IND
Phase I
Phase II
Phase III
Vaxxine Program (Target)
Indications
Hypercholesterolemia
10%
Preclinical
IND
Phase I
Phase II
Phase III
Marketed

Vaxxine Program
(Target)

Indications

Preclinical

IND

Phase I

Phase II

Phase III


Novel Targets

2019
2H 2020
2019
2H 2020
2019
2H 2020
2019
2H 2020

Novel Targets

2019
2H 2020
2019
2H 2020